Molecular Approaches to Developing a Vaccine for Leprosy
Leprosy, a chronic infectious disease afflicting 10 million to 15 million people, is caused by the obligate intracellular parasite Mycobacterium leprae. Although M. leprae was the first identified bacterial pathogen of man, it remains one of the few human pathogens that cannot yet be grown in culture. The inability to grow leprosy bacillus in culture has severely limited the understanding of the bacillus and the disease.
KeywordsToxicity Amide Tuberculosis Electrophoresis Bacillus
Unable to display preview. Download preview PDF.
- 1.Abou-Zeid C, Filley E, Steele J, Rook GAW: A simple new method for using antigens separated by Polyacrylamide gel electrophoresis to stimulate lymphocytes in vitro after converting bands cut from Western blots into antigen- bearing particles. J Immunol Methods 1987; 98: 5–10.PubMedCrossRefGoogle Scholar
- 5.Chaudhuri S, Fotedar AR, Talwar GP: Lepromin conversion in repeatedly lepromin negative BL/LL patients after immunization with autoclaved Mycobacterium w. Int J Lepr 1983; 51: 159–168.Google Scholar
- 6.Convit J, Aranzazu N, Ulrich M, et al: Immunotherapy with a mixture of Mycobacterium leprae BCG in different forms of leprosy and in Mitsuda-negative contacts. Int J Lepr 1982; 50: 415–424.Google Scholar
- 10.Engers HD, Abe M, Bloom BR, et al: Workshop: results of a World Health Organization-sponsored workshop on monoclonal antibodies to Mycobacterium leprae. Infect Immun 1985; 48: 603–605.Google Scholar
- 11.Fine PEM: The role of BCG in the control of leprosy. Ethiop Med J 1985; 23: 179–191.Google Scholar
- 25.Mustafa AS, Gill HK, Nerland A, et al: Human T-cell clones recognize a major M. leprae protein antigen expressed in E. coli. Nature 1986; 319: 63–66.Google Scholar